In this module, we explore Nuclear Medicine - from imaging techniques to treatments for diseases such as cancer. Discover what medical physicists do; find out how PET scanners work, and how quantum entanglement can make these more effective; and use computer modelling to investigate proton-beam therapy and optimise treatment.
5.1 Medical Imaging (Questions)
5.2 Medical Treatments (Questions)
5.3 Modelling Radiotherapy (Online Simulation)
5.4 Modelling Radiotherapy (Questions)
In this short introductory video, Dr. Laura Sinclair explains the role of a medical physicist and the applications of nuclear medicine.
Radioactive material attached to a drug is known as a radiopharmaceutical. In imaging, radiopharmaceuticals may be injected, inhaled, or swallowed in capsule form. Radiopharmaceuticals can be used as tracers to see how well organs in your body are working or to find areas of disease. For a tracer, a radionuclide is mixed with a drug that collects in a particular organ in the body. Then, by detecting the radiation, we can examine that organ.
A gamma camera detects the radiation coming from the patient and produces an image of where the radioactivity is in the body. By displaying the position of each gamma ray that it detects, the gamma camera can build up a full image.
The radionuclide technetium-99m (Tc-99m) is known as the workhorse in diagnostic nuclear medicine because it is used so frequently and can be attached to a range of pharmaceuticals. The m in Tc-99m stands for metastable, (explained below). It is suited to this role as it's relatively short-lived (half life of 6.022 hours) and it emits readily detectable gamma rays with a photon energy of 140.5 keV. This allows for rapid data collection/image taking and keeps the total patient radiation exposure low.
Technetium-99m is produced by the decay of molybdenum-99 (Mo-99), a radionuclide with a longer half-life of 66 hours. Mo-99 is usually created commercially by fission of highly enriched uranium. The radionuclide Mo-99 decays via beta-minus decay 87.6% of the time into the 142.7 keV excited state, Tc-99m. Then Tc-99m decays to Tc-99, which has a half-life of 211,100 years. A lot of Tc-99m leaves the body through urine (and small amounts in sweat and salvia). In the hospital, there are 'hot' toilets especially for this radioactive waste!
Metastable states are almost always excited states (there are a few weird exceptions, but let’s not go into that!). This means that it has excess energy that it needs to get rid of. These can decay either to a lower lying state in the nucleus (typically by gamma emission) or decay via another mechanism, such as beta decay. In the case of Tc-99m, the situation is slightly complicated by the fact that the gamma-decay of the 99mTc state is so suppressed that it actually gets rid of some of its energy by emitting an atomic electron first: a process called internal conversion. This helps it get rid of about 2.2 keV, decaying to a state just below it, which has a fast gamma decay with the 140.5 keV gamma-ray mentioned above. It is this secondary gamma-decay that medical physicists use for diagnostics.
The process is shown in figure 1 below:
Figure 1: Decay modes of Mo-99 into Tc-99
Due to the short half-life of Tc-99m and the distance from a nuclear reactor, storage and transport of this radionuclide would be inconvenient and very expensive. Instead, the parent nuclide, Mo-99, is supplied to hospitals for use in a generator, known as a Mo-Tc generator. Within the generator the parent radionuclide, Mo-99, decays into the shorter-lived daughter radionuclide, Tc-99m. The 'daughter' radionuclide is removed by passing a solution of saline (salt-water) through the generator. This is known as elution. The saline solution elutes (removes) the soluble Tc-99m, which results in a saline solution containing the Tc-99m. The activity of the Mo-Tc generator, eluded every 24 hours, can be seen in the graph in figure 2 below:
Figure 2: Activity of a Mo-Tc generator over time
The Administration of Radioactive Substances Advisory Committee (ARSAC) provides a set initial activity of Tc-99m for patients known as a diagnostic reference level (DRL), which is measured in Becquerel (Bq). Typically, for diagnostic investigations, the DRL ranges from kBq to MBq depending on the type of examination. If the activity administered is too high, this may give an unnecessary radiation dose to the patient and could overwhelm the gamma camera, meaning anything relevant could be obscured. However, if the activity administered is too low, the gamma camera may not be sensitive enough and a diagnosis could be missed as a result. Therefore, the patient has to be administered the radiopharmaceutical within a set time frame to ensure the correct DRL.
In this video, Ruth Newton from the University of York gives an introduction to PET scans and talks about her research into using quantum entanglement to improve the quality of PET scans for diagnostic medicine.
Log in to Isaac Physics and answer the questions:
Medical Imaging I
Medical Imaging II
Medical Imaging III
Medical Imaging IV
Don't forget to log in to Isaac Physics!
Please note that the information, video, and activity below are based around radiotherapy treatments for cancer. There are many factors that affect treatment plans, and the content below is not intended to replace medical advice. If you have been personally affected by cancer and would rather not engage with this content, please let us know by emailing physics-bindingblocks@york.ac.uk (so that you may still receive your certificate).
As described in Laura's video above, Nuclear Medicine can be used for treatment as well imaging.
Radiotherapy is a form of cancer treatment that kills cancer cells by depositing large amounts of energy into the cells, thus ionising the atoms in the cell DNA. Photons (X-rays) or charged particles are used as sources of ionising radiation.
In the video below, Matthew Nicol from the University of York introduces radiotherapy before focusing on proton beam therapy.
The X-rays used for radiotherapy are highly penetrating and highly ionising forms of electromagnetic radiation. They have enough energy to radicalise (tear an electron away from) oxygen and hydrogen pairs (known as hydroxy groups) in cell DNA. This radicalisation eventually leads to the cell not being able to replicate or repair itself, and the cell dies. This is desirable when the cell is a cancer cell, but one of the problems with X-ray radiotherapy is that the ionisation (or radicalisation) is not exclusive to cancer cells. The X-rays damage healthy cells as well and, as X-rays are highly penetrating, they deposit energy and ionise atoms over a large area.
X-Rays can be thought of as composed of packets of energy called photons. We can calculate the energy of a photon (E) based on its wavelength (λ) using the equation:
Here, h is Planck’s constant (h = 6.63 x 10-34 Js) and c is the speed of light in a vacuum (c = 3 x 108 ms-1). In order to compare photon and proton energies, we can convert this energy into electron-volts (eV) where 1 eV = 1.6 x 10-19 J.
Figure 3 (below) shows the relative dose to tissue versus the tissue depth for X-ray photons and protons.
Figure 3: A graph showing relative dose to tissue against the tissue depth for X-rays and protons. Image source
You can see that X-rays deposit a far higher dose to healthy cells and a much lower dose to cancer cells. This is mitigated by having a rotating X-ray source. This method allows for the target area (cancer cells) to receive multiple doses whilst different areas of healthy tissue only receive two (one high when the X-Ray enters through that direction, and one lower when it leaves through that direction). The patient will also have a personalised radiotherapy treatment plan, which is broken into several treatments. This is to help healthy tissue repair and to kill cancer cells. A medical physicist or dosimetrist will plan the treatment based on the patient's CT scan (and sometimes MRI/CT and PET/CT scans are used too). There are limits of radiation dose to organs near the tumour (known as organs-at-risk). Very commonly, there is microscopic growth of tumours which can't be detected by imaging, so a volume around the tumour has to be included. Treatments can occur over 20 minutes so during this time patients move about, their chest moves when they breathe, and if they are undergoing chemotherapy or other treatments they may lose or gain weight rapidly. On a day-to-day basis, how much patients have drunk or eaten can also cause differences in the internal organs. These things can all have an effect on the treatment plan.
Proton therapy involves firing highly energetic protons at target cancer cells. These protons directly damage the cancer cell by depositing a large amount of energy onto them and, due to their relatively high mass, they scatter only a very short distance before stopping, minimizing damage to the surrounding tissue. Just like X-rays, high energy proton beams ionise atoms as they pass through the body but, unlike X-rays, the doses are relatively low until right before they stop (where they will deposit the majority of their energy). This creates the peak in the relative dose versus depth in tissue that you can see in figure 3 (above). This is called the Bragg Peak effect.
However, there are disadvantages to proton therapy. The high precision of the dose means that treatment plans have to be meticulously planned. It also makes it difficult to use for cancers in areas where there is a lot of body or organ movement, for example the lungs, where the motion of breathing actively varies the depth of a tumour. The high precision of a single energy proton beam will also not target the entire tumour. For that, you need several proton beams at different energies to create different depth Bragg Peaks that can overlay each other and Spread Out the Bragg Peak (SOBP). You can see relative dose versus depth in tissue for a SOBP in figure 3 (above). The tissue before the cell also receives a cumulative dose from all the proton beams.
Log in to Isaac Physics and answer questions on
Medical Treatments I
Medical Treatments II
Medical Treatments III
Don't forget to log in to Isaac Physics!
With all forms of radiotherapy, it is crucially important to target the radiation so that the energy is deposited in the cancer tumour, and does minimal damage to healthy tissue. One method we can take to find the correct beam energies is to simulate hitting a tumour using computer software. This allows us to safely experiment with different settings without putting a patient at risk. An example of a proton hitting a target using GEANT4 (a CERN simulation toolkit) is shown in figure 4 below:
Figure 4: Visualisation of GEANT4 simulation of a proton in air
We can pull meaningful data out from these simulations by putting them into different software which analyses the data. These software packages look at the data and allow us to see how the energy deposition changes with depth into the material and the divergence from the beam line for different particles. This analysis takes files that are over 80 gigabytes in size (each!) and turns them into graphs which are a couple of megabytes - far easier to store!
We have used these GEANT4 simulations to create a web application that allows you to simulate these ground-breaking treatment methods, as well as explore other properties of radiation, in real time. The app is simple to use, requiring only a couple of inputs to generate real data. Let's say, for example, we needed to find the range of a proton in water:
Figure 5: Annotated screenshot from the simulation, showing parameters that can be controlled
There are three different outputs from the simulation. The graph in figure 6, below, shows the energy deposited (y-axis) as you move through the material (depth of material on the x-axis). The particles in the beam will deposit energy when they are absorbed into the material. This means that the particles do not travel any further.
Figure 6: Annotated screenshot from the simulation showing a graph of Energy Deposition vs Depth
In figure 7, below, we see an example of a 2D energy distribution as a function of z (depth) and r (width) for a 100 MeV proton beam in water. Colour coding shows how much energy is deposited - where red is a large amount of energy and blue is less. The energy is mostly deposited along the beam line. However, a significant portion of protons deposit their energy out to a radius of approximately 30 mm. The proton distribution is almost wedge-shaped, with the broadest part of the distribution falling near the end of the proton track. Outside this region, we see that the energy deposition becomes almost constant, but at a much lower level than the proton peak.
Figure 7: Depth vs distance from beam centre for a 100 MeV proton in water
The final graphical interface you can select shows the particle tracks, taken from the GEANT4 software.
Use the Radiotherapy Simulation to study how the energy deposition, and therefore dose and damage to tissue, is distributed using different types of radiation. Focus on X-rays and protons, particularly considering their interaction with human cells (soft tissue). Look at how the energy deposition changes depending on the type of radiation. Investigate the effect of the energy of the radiation and the type of material that is targeted.
Note that the units of energy used here are MeV (mega electron volts). One electron volt is the energy gained by an electron when accelerated by a potential difference of one volt, or 1 eV = 1.6 x 10-19 J.
Once you have investigated a variety of effects present in radiation treatments, answer the following questions (activity 5.4).
Log in to Isaac Physics and answer the questions:
Simulation Question I
Simulation Question II
Simulation Question III
You will need to use the simulation above to generate "Energy Deposition vs Depth" figures and "Energy Deposition vs Distance from Beam Line" to answer these questions!
Don't forget to log in to Isaac Physics!
You can find out more about proton beam therapy from the Christie, an NHS hospital in Manchester and one of Europe's leading cancer centres: What is proton beam therapy?
At the CERN-MEDICIS facility, CERN has now initiated a programme to develop new medical isotopes. This is based on the CERN ISOLDE facility, where radioactive isotopes are also produced for fundamental nuclear science (and which you can hear more about in Module 2). The MEDICIS facility takes its name from MEDical Isotopes Collected from ISolde, and they produce the isotopes using the a 1.4 GeV proton beam produced at CERN [Duchemin et al., Frontiers in Medicine 8, 693682 (2021)]. The isotopes are used in treatment or diagnosis by delivering them to the cancer cells using a chemical that targets this particular type of cancer cell. You can read more about this targeted treatment in the optional case study below on Astatine-211.
One of the key focus areas at MEDICIS and other recent programmes for medical radioisotope production is the production of the so-called 'theranostic' isotopes. This requires a combination of therapeutic isotopes for treatment integrated with diagnostic isotopes. This is particularly done by developing different isotopes of the same element that can be used with the same chemical targeting, with some of these isotopes for diagnosing cancer and some for treating cancer. Since isotopes of the same element have the same chemical properties, we know that the cancer diagnosed by the delivery of the diagnostic drug will be treated just as effectively by the same delivery of the treatment isotope [Biggin et al., Journal of Nuclear Medicine 58, 1014 (2017)].
Professor Andrei Andreyev, from the University of York, has worked with a team of scientists at CERN to study the atomic structure of astatine. Astatine is the rarest naturally occurring element on Earth, with a total abundance estimated to be only 0.07g. Before their study, it was the only naturally occurring element whose ionisation energy hadn’t been measured. Ionisation energy is an important property to study because it determines the chemical reactivity of the element as well as its stability in compounds. The value determined for astatine can now be used to help predict the atomic and chemical properties of other super-heavy elements. The ionization energy was found by creating short-lived isotopes of astatine using particle accelerators at CERN and firing lasers at the astatine atoms. The atoms were excited through each excitation level by absorbing photons until the energy exceeded its ionisation energy. The radioactive isotope astatine-211 is particularly interesting in medicine because it is a potential radiation source for targeted alpha therapy. Alpha therapy is starting to be used in cancer treatment. Alpha radiation can cut through DNA and causes cells to stop dividing and die. In targeted alpha therapy, radioactive isotopes that emit alpha particles are attached to carrier molecules which accumulate in tumour cells. The molecules can selectively target cells they recognize as cancer and bond to them. As alpha particles have a high energy but do not travel very far in human tissue (less than 0.1mm) they are able to target and destroy specific cancer cells while minimising damage to the healthy tissue surrounding the tumor.
Fluorine-18 is of particular interest both in nuclear medicine and nuclear astrophysics. In nature, fluorine-18 is produced in one of the most violent explosions in our galaxy - a novae explosion, and indeed fluorine-18 production in the universe has now been observed using space telescopes. Dr Alison Laird has led experiments which determine how fluorine-18 is produced and destroyed in nova explosions, and she has shown how this can be used to model the explosions and how far away we will be able to detect individual explosions. Artificially produced fluorine-18 is critical in medical imaging, specifically in Positron Emission Tomography (PET) scanners. These scans exploit fluorine-18’s beta+ decay to correlate the location of objects of interest in the body from the photons emitted in the annihilation of the positron (from the beta+ decay) and an electron in the body. Over recent years, integrated PET and Magnetic Resonance Imaging (MRI) machines have been developed. These have significant medical advantages because both improved functional and anatomical information can be gathered simultaneously, improving diagnostics and leading to more effective treatment. To achieve this, the scanner requires light sensors (scintillators) which are insensitive to magnetic fields. Such sensors have been developed at the University of York by Prof. David Jenkins and his team of researchers.
References: A.M. Laird, et al., Is γ-ray emission from novae affected by interference effects in the 18F(p,α)15O reaction? Phys. Rev. Lett. 110, 032502 (2013); D. Jenkins Novel Scintillators and Silicon Photomultipliers for Nuclear Physics and Applications, 2015 J. Phys.: Conf. Ser. 620 012001 (2015).